Indazole [3, 2-a] isoquinoline compound with anticancer activity and synthesis method thereof

By using specific catalysts and raw materials under mild conditions, the problems of low efficiency and insufficient structural diversity of indazole [3,2-a] isoquinoline compounds in the prior art were solved, and efficient synthesis was achieved Anti-cancer activity compounds provide new pharmaceutical ingredients for cancer treatment.

CN119080767APending Publication Date: 2024-12-06HENAN NORMAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411178123.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art synthesis of indazole [3,2-a] isoquinoline compounds has problems such as using highly functionalized substrates, complicated reaction steps, low efficiency, limited structural diversity and many by-products, making it difficult to achieve high efficiency. , economical preparation method.

Method used

Using 3-aryl-1H-indazole compounds and fluoromethylimine sulfoxide or substituted formyl sulfoxide as raw materials, the indazole is achieved through catalytic reaction under mild conditions and specific catalysts and additives [3] ,2-a] high-efficiency synthesis of isoquinoline compounds.

Benefits of technology

Indazole [3,2-a]isoquinoline compounds with anti-cancer activity are provided, which simplifies the synthesis process, improves the structural diversity and medicinal value of the products, and provides the treatment of cervical, lung and colon cancer. New drug ingredients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080767A_ABST
    Figure CN119080767A_ABST
Patent Text Reader

Abstract

The invention discloses an indazole [3, 2-a] isoquinoline compound with anticancer activity and a synthesis method thereof, and belongs to the technical field of organic synthesis and drug discovery. The chemical structural general formula of the indazole [3, 2-a] isoquinoline compound 3 and the indazole [3, 2-a] isoquinoline compound 5 is # imgabs0, the indazole [3, 2-a] isoquinoline compound 3 and the indazole [3, 2-a] isoquinoline compound 5 are respectively synthesized through a one-pot cascade reaction of a 3-aryl-1H-indazole compound 1 and a substituted formyl sulfoxide ylide 2 or fluoromethyl imine sulfoxide ylide 4, and the process is simple and efficient; the compounds can significantly inhibit the growth and proliferation of Hela, A549 and HCT-116, which indicates that the compounds as active ingredients of anti-cancer drugs have the effects of preventing, treating and inhibiting progress deterioration of cervical cancer, lung cancer and colon cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of organic synthesis and drug discovery, and specifically relates to indazole [3,2-a] isoquinoline compounds with anticancer activity and a synthesis method thereof. Background Art

[0002] As bioisosteres of indole, indazole compounds have diverse pharmaceutical activities, and many clinical drug molecules contain indazole as a structural unit. Indazole derivatives also have unique physical and chemical properties and are often used to prepare functional dyes, semiconductor materials, and photovoltaic materials. On the other hand, isoquinoline is the core structural skeleton of many natural products and drugs and is one of the important sources for new drug discovery. Therefore, the design and synthesis of indazole [3,2-a] isoquinoline compounds that combine these two advantageous structural units have important theoretical significance and application prospects.

[0003] At present, some effective methods for preparing indazole [3,2-a] isoquinoline compounds have been developed, mainly including: 1) [3+2] cycloaddition reaction of isoquinoline imine and aromatic alkyne; 2) tandem reaction of N'-(2-alkynyl-benzylidene) hydrazide and polyfluoroaromatic hydrocarbons; 3) triethyl phosphite-mediated intramolecular reductive cyclization reaction of 1-(2-nitrophenyl) isoquinoline, etc. Although these literature methods are generally reliable, they still have the disadvantages of requiring the use of highly functionalized substrates, cumbersome reaction steps, low overall efficiency, limited product structure diversity, and many by-products.

[0004] Based on the above background, studying and developing a new atom-economical method for synthesizing indazole [3,2-a] isoquinoline compounds from simple and readily available raw materials under mild conditions, and studying their biological activity and medicinal value in order to discover new lead compounds, not only has important theoretical significance, but also has important application value. Summary of the invention

[0005] In order to solve the problems existing in the prior art, one of the objectives of the present invention is to provide indazole [3,2-a] isoquinoline compounds, which have anticancer activity.

[0006] The second object of the present invention is to provide the use of indazole [3,2-a] isoquinoline compounds in the preparation of anticancer drugs.

[0007] The third object of the present invention is to provide a pharmaceutical composition for treating cervical cancer, lung cancer and colon cancer, wherein the active ingredient is the indazole [3,2-a] isoquinoline compound provided by the present invention.

[0008] A fourth object of the present invention is to provide a method for synthesizing indazole [3,2-a] isoquinoline compounds.

[0009] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0010] Indazole [3,2-a] isoquinoline compounds 3 and 5 have the general chemical structure formula:

[0011]

[0012] Where: R 1 For hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen, trifluoromethyl or cyano, which is mono- or poly-substituted or forms a naphthalene ring with the benzene ring; R 2 is phenyl, substituted phenyl, naphthyl, cyclohexyl, trifluoromethyl or pentafluoroethyl, and the substituent on the phenyl ring of the substituted phenyl is a mono- or poly-substituted phenyl, C 1-4 Alkyl, C 1-4 Alkoxy, trifluoromethyl, halogen (fluorine, chlorine, bromine, iodine) or methylenedioxy; R 3 is phenyl, substituted phenyl or naphthyl, the substituent on the phenyl ring of the substituted phenyl is C 1-4 Alkyl, C 1-4 Alkoxy, halogen, trifluoromethyl or nitro; R 4 is fluorine or trifluoromethyl.

[0013] Furthermore, in the above general structure, in the most preferred case, the following specific structures are selected:

[0014]

[0015] The present invention designs experiments to verify that the compounds provided by the present invention have the activity of inhibiting the proliferation of three cancer cells, Hela, A549 and HCT-116, indicating that the compounds of the present invention can be used as active ingredients of drugs for treating cancers such as cervical cancer, lung cancer and colon cancer. In particular, the above-mentioned preferred compounds can significantly inhibit the growth and proliferation of Hela, A549 and HCT-116, indicating that such compounds as active ingredients of anticancer drugs have the effects of preventing, treating and inhibiting the progression of cervical cancer, lung cancer and colon cancer.

[0016] The present invention also provides a method for synthesizing an indazole [3,2-a] isoquinoline compound 5, which is prepared using a 3-aryl-1H-indazole compound 1 and a fluoromethyl-substituted imine sulfoxide ylide compound 4 as raw materials; the method specifically comprises the following steps: mixing the 3-aryl-1H-indazole compound 1, the fluoromethyl imine sulfoxide ylide 4, a catalyst, an additive and an organic solvent, and heating the mixture to obtain the fluoromethyl-substituted indazole [3,2-a] isoquinoline compound 5, wherein the reaction equation is:

[0017]

[0018] Where: R 1 For hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen, trifluoromethyl or cyano, which is mono- or poly-substituted or forms a naphthalene ring with the benzene ring; R 3 is phenyl, substituted phenyl or naphthyl, the substituent on the phenyl ring of the substituted phenyl is C 1-4 Alkyl, C 1-4 Alkoxy, halogen, trifluoromethyl or nitro; R 4 is fluorine or trifluoromethyl.

[0019] Furthermore, in the above technical solution, the additive is bis(trifluoromethanesulfonyl)imide silver salt, silver hexafluoroantimonate, cesium acetate or silver acetate.

[0020] Furthermore, in the above technical solution, the organic solvent is preferably methanol, trifluoroethanol or 1,2-dichloroethane.

[0021] Furthermore, in the above technical scheme, the catalyst is dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer ([RhCp*Cl2]2), dichlorobis(4-methylisopropylphenyl)ruthenium(II) dimer ([Ru(p-cymene)Cl2]2) or dichloro(pentamethylcyclopentadienyl)iridium(III) dimer ([IrCp*Cl2]2).

[0022] Furthermore, in the above technical scheme, the molar ratio of the 3-aryl-1H-indazole compound 1, the fluoromethylimide sulfoxide ylide 4, the catalyst and the additive is 1:1-2:0.015-0.03:0.12-0.32.

[0023] Furthermore, in the above technical solution, the reaction temperature is 100-140°C.

[0024] The present invention also provides a method for synthesizing the above-mentioned indazole [3,2-a] isoquinoline compound 3, which is prepared using a 3-aryl-1H-indazole compound 1 and a substituted formyl sulfoxide ylide 2 as raw materials, or by removing the amino group of compound 5 in the presence of a base; specifically, the following two schemes are included:

[0025] Method A: Mix a 3-aryl-1H-indazole compound 1, a substituted formyl sulfoxide ylide 2, a catalyst, an additive and an organic solvent, and heat the mixture to obtain an indazole [3,2-a] isoquinoline compound 3. The reaction equation is:

[0026]

[0027] Where: R 1 For hydrogen, C 1-4 Alkyl, C1-4 Alkoxy, phenyl, halogen, trifluoromethyl or cyano, which is mono- or poly-substituted or forms a naphthalene ring with the benzene ring; R 2 is phenyl, substituted phenyl, naphthyl, cyclohexyl, trifluoromethyl or pentafluoroethyl, and the substituent on the phenyl ring of the substituted phenyl is a mono- or poly-substituted phenyl, C 1-4 Alkyl, C 1-4 Alkoxy, trifluoromethyl, halogen or methylenedioxy.

[0028] Furthermore, in the above technical solution, the additive is zinc trifluoromethanesulfonate or lithium trifluoromethanesulfonate.

[0029] Furthermore, in the above technical solution, the organic solvent is a mixed solvent, preferably a mixed solvent consisting of acetic acid and trifluoroethanol, chlorobenzene or 1,2-dichloroethane.

[0030] Furthermore, in the above technical scheme, the catalyst is dichloro(pentamethylcyclopentadienyl)rhodium(III) dimer ([RhCp*Cl2]2), di(hexafluoroantimonate)triacetonitrile(pentamethylcyclopentadienyl)rhodium ([RhCp*(CH3CN)3](SbF6)2) or dichloro(pentamethylcyclopentadienyl)iridium(III) dimer ([IrCp*Cl2]2).

[0031] Furthermore, in the above technical solution, the molar ratio of the 3-aryl-1H-indazole compound 1, the substituted formyl sulfoxide ylide 2, the catalyst and the additive is 1:1-1.5:0.01-0.025:0.5-2.

[0032] Furthermore, in the above technical solution, the reaction temperature is 80-120°C.

[0033] Method B: Indazole [3,2-a] isoquinoline compound 5 is reacted at elevated temperature in an organic solvent in the presence of a base to obtain indazole [3,2-a] isoquinoline compound 3. The reaction equation is:

[0034]

[0035] Where: R 1 -R 4 The substituents are the same as described above.

[0036] Furthermore, in the above technical solution, the base is selected from silver acetate; and the organic solvent is trifluoroethanol.

[0037] Furthermore, in the above technical solution, the reaction temperature is 120-150°C.

[0038] Beneficial effects of the invention:

[0039] (1) The indazole [3,2-a] isoquinoline compounds provided by the present invention are screened for compounds having various substituents and verified by anticancer cell activity tests. The compounds provided by the present invention have the activity of significantly inhibiting the proliferation of three cancer cells, namely Hela, A549 and HCT-116, indicating that the compounds of the present invention have anticancer activity against cervical cancer, lung cancer and colon cancer, have potential medicinal value, and provide new structural units for drug screening;

[0040] (2) The synthesis method provided by the present invention is to synthesize indazole [3,2-a] isoquinoline compounds 3 and 5 respectively through a one-pot tandem reaction of a 3-aryl-1H-indazole compound 1 and a substituted formyl sulfoxide ylide 2 or a fluoromethylimide sulfoxide ylide 4. The process is simple and efficient;

[0041] (3) The synthetic method provided by the present invention has cheap and readily available raw materials, mild reaction conditions, simple operation, a wide range of substrate applicability, and good functional group tolerance.

[0042] Instruction Manual

[0043] Figure 1 It is the X-ray single crystal diffraction pattern of compound 5aa in Example 4 and Example 5.

[0044] Figure 2 This is the X-ray single crystal diffraction pattern of compound 3A in Example 7. DETAILED DESCRIPTION

[0045] The above contents of the present invention are further described in detail below through examples, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples, and all technologies implemented based on the above contents of the present invention belong to the scope of the present invention.

[0046] Example 1

[0047]

[0048] Compound 1a, organic solvent, catalyst, additive and 2a were added to a 15 mL reaction tube in sequence, the reaction tube was sealed, and the reaction was stirred in an oil bath to react. After the reaction was completed, it was cooled to room temperature, water was added to quench the reaction, and it was extracted with dichloromethane. The organic phase was dried, filtered, concentrated, and separated by a silica gel column (petroleum ether / ethyl acetate = 30:1) to obtain a yellow solid product 3aa.

[0049] By changing the reaction conditions such as the catalyst, additives, organic solvent and the amount of each substance, a series of results were obtained, as shown in Table 1.

[0050] Table 1 Synthesis of 3aa under different conditions a

[0051]

[0052]

[0053] Example 2

[0054]

[0055] 1a (19.4 mg, 0.1 mmol), acetic acid (29 μL, 0.5 mmol), trifluoroethanol (1 mL), [IrCp*Cl2]2 (1.2 mg, 0.0015 mmol), zinc trifluoromethanesulfonate (36.4 mg, 0.1 mmol) and 2a (19.6 mg, 0.1 mmol) were added to a 15 mL pressure tube in sequence, and then the reaction tube was sealed and placed in a 100 ° C oil bath for 12 h. After the reaction, the reaction system was cooled to room temperature, water was added to quench the reaction, and dichloromethane was extracted three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered through diatomaceous earth, and the filtrate was concentrated and separated by a silica gel column (petroleum ether / ethyl acetate = 30:1) to obtain a yellow solid product 3aa (24 mg, 82%). The characterization data of this compound are: 1 HNMR (CDCl3, 400MHz): δ8.74(d,J=8.0Hz,1H),8.51(d,J=8.4Hz,1H),8.02(d,J=6.8Hz,2H),7.98(d,J=8.8H z,1H),7.90(d,J=7.6Hz,1H),7.76(t,J=7.2Hz,1H),7.64-7.53(m,5H),7.45(s,1H),7.36(t,J=7.6Hz,1H). 13 C{ 1 H}NMR(CDCl3,100MHz): δ148.9,138.5,134.0,131.5,129.8,129.6,128.6,128.5,128.2,12 7.7,127.24,127.19,125.7,122.7,121.5,121.2,117.8,116.9,116.8.HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 15 N2295.1230; Found 295.1236.

[0056] Example 3

[0057] According to the method and steps of Example 2 a,bBy changing reactant 1 and reactant 2, various indazole [3,2-a] isoquinoline compounds 3 were synthesized. The specific results are as follows:

[0058]

[0059] a Reaction conditions: 1 (0.1 mmol), 2 (0.1 mmol), [IrCp*Cl2]2 (0.0015 mmol), acetic acid (0.5 mmol), zinc trifluoromethanesulfonate (0.1 mmol), trifluoroethanol (1 mL), 100 °C, 12 h, air atmosphere; b Isolated yield.

[0060] Representative product characterization data are as follows:

[0061] 3-Ethyl-6-phenylindazolo[3,2-a]isoquinoline(3ba)

[0062] 1 H NMR (CDCl3, 400 MHz): δ8.61 (d, J = 8.4 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.00-7.98 (m, 2H), 7.93 (d, J = 8.8 Hz,1H),7.65(s,1H),7.58-7.48(m,5H),7.37(s,1H),7.30(t,J=8.0 Hz,1H),2.84(q,J=7.6 Hz,2H),1.35(t,J=7.6 Hz,3H). 13 C{ 1 H}NMR(CDCl3,100MHz): δ148.9,143.6,138.4,134.2,131.7,129.8,129.5,128.93,128.91,128.5 ,127.1,126.0,123.8,122.7,121.2,121.1,117.6,116.9,116.5,29.0,15.5.HRMS(ESI)m / z:[M+H] + Calcd for C 23 H 19 N2323.1543; Found 323.1545.

[0063] 3,6-Diphenylindazolo[3,2-a]isoquinoline(3ca)

[0064] 1H NMR(CDCl3,400 MHz):δ8.73(d,J=8.4 Hz,1H),8.48(d,J=8.4 Hz,1H),8.05(d,J=1.6 Hz,1H),8.01-7.99(m,2H),7.96(d,J=8.4 Hz,2H),7.73(d,J=7.2 Hz,2H),7.59-7.48(m,6H),7.46(s,1H),7.41(t,J=7.2 Hz,1H),7.33(t,J=7.6 Hz,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ149.0,140.2,139.9,138.8,134.0,131.4,128.8,129.6,129.10,129.06,128.6,127.9,127.5,127.33,127.28,125.6,124.7,123.2,121.5,121.2,117.8,117.0,116.8.HRMS(ESI)m / z:[M+H] + Calcd for C 27 H 19 N2371.1543;Found 371.1542.

[0065] 3-Fluoro-6-phenylindazolo[3,2-a]isoquinoline(3da)

[0066] 1 H NMR(CDCl3,400 MHz):δ8.57(dd,J1=8.8 Hz,J2=1.2 Hz,1H),8.30(d,J=8.4Hz,1H),7.91-7.88(m,2H),7.85(d,J=8.8 Hz,1H),7.51-7.34(m,6H),7.25-7.21(m,2H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ161.3(d, 1 J C-F =247.0 Hz),149.0,139.5,133.7,131.3,130.2(d, 3 J C-F =8.7 Hz),129.8,129.7,128.6,127.4,124.9(d, 3 J C-F =8.7Hz),122.5(d, 4 JC-F =2.1 Hz),121.6,120.9,117.8,117.1(d, 2 J C-F =23.8 Hz),116.3,115.9(d, 4 J C-F =3.7Hz),112.3(d, 2 J C-F =21.0 Hz). 19 F NMR(CDCl3,565 MHz):δ-112.30–-112.34(m).HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 14 FN2313.1136;Found 313.1133.

[0067] 3-Chloro-6-phenylindazolo[3,2-a]isoquinoline(3ea)

[0068] 1 H NMR(CDCl3,400 MHz):δ8.51(d,J=8.8 Hz,1H),8.33(d,J=8.4 Hz,1H),7.96-7.91(m,3H),7.77(d,J=1.2 Hz,1H),7.61-7.53(m,4H),7.51-7.47(m,1H),7.29(t,J=7.6Hz,1H),7.26-7.23(m,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ149.0,139.5,133.6,132.8,131.0,129.8,129.7,129.6,128.6,127.4,126.7,124.0,123.9,121.8,120.8,117.9,116.6,115.6.HRMS(ESI)m / z:[M+H] + Calcd forC 21 H 14 ClN2329.0840;Found 329.0851.

[0069] 3-Bromo-6-phenylindazolo[3,2-a]isoquinoline(3fa)

[0070] 1H NMR(CDCl3,400 MHz):δ8.53(d,J=8.8 Hz,1H),8.39(d,J=8.4 Hz,1H),8.01-7.94(m,4H),7.80(dd,J1=8.4 Hz,J2=1.6 Hz,1H),7.60-7.50(m,4H),7.36-7.31(m,2H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ149.0,139.5,133.6,131.3,131.1,130.0,129.9,129.7,128.6,127.5,124.3,124.1,121.9,120.95,120.87,117.9,116.7,115.5.HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 14 BrN2373.0335;Found373.0337.

[0071] 6-Phenyl-3-(trifluoromethyl)indazolo[3,2-a]isoquinoline(3ga)

[0072] 1 H NMR(CDCl3,400 MHz):δ8.70(d,J=8.4 Hz,1H),8.38(d,J=8.4 Hz,1H),8.11(s,1H),7.98-7.94(m,3H),7.88(d,J=8.4 Hz,1H),7.58-7.50(m,4H),7.41(s,1H),7.34(t,J=7.6 Hz,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ148.9,139.8,133.4,130.6,130.0,129.7,128.7(q, 2 J C-F =32.5 Hz),128.6,127.9,127.5,127.4,124.9(q, 3 J C-F =4.3 Hz),124.12(q, 3 J C-F =2.9 Hz),124.09(q, 1 J C-F=270.8 Hz),123.2,122.4,120.7,118.1,117.1,116.3. 19 F NMR(CDCl3,565 MHz):δ-62.15(s).HRMS(ESI)m / z:[M+H] + Calcd forC 22 H 14 F3N2363.1104;Found 363.1105.

[0073] 6-Phenylindazolo[3,2-a]isoquinoline-3-carbonitrile(3ha)

[0074] 1 H NMR(DMSO-d6,400 MHz):δ9.04(d,J=8.4 Hz,1H),8.77(d,J=8.8 Hz,1H),8.68(d,J=1.6 Hz,1H),8.16(dd,J1=8.4 Hz,J2=1.6 Hz,1H),8.00-7.98(m,2H),7.95(d,J=8.4 Hz,1H),7.89(s,1H),7.66-7.61(m,4H),7.49-7.45(m,1H). 13 C{ 1 H}NMR(CDCl3,150MHz):δ149.1,140.4,133.1,132.3,130.5,130.2,129.8,129.7,128.7,128.0,127.80,127.78,123.4,123.0,120.7,118.7,118.4,117.4,115.6,110.2.HRMS(ESI)m / z:[M+H] + Calcd for C 22 H 14 N3320.1182;Found 320.1181.

[0075] 2-Chloro-6-phenylindazolo[3,2-a]isoquinoline(3ia)

[0076] 1H NMR(CDCl3,400 MHz):δ8.62(d,J=1.2 Hz,1H),8.42(d,J=8.8 Hz,1H),7.99-7.94(m,3H),7.78(d,J=8.4 Hz,1H),7.60-7.51(m,5H),7.38-7.34(m,2H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ148.9,138.7,134.1,133.7,130.3,129.9,129.8,129.7,129.0,128.6,127.7,127.4,126.8,126.5,122.0,120.8,117.9,116.8,116.1.HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 14 ClN2329.0840;Found 329.0844.

[0077] 4-Fluoro-6-phenylindazolo[3,2-a]isoquinoline(3ja)

[0078] 1 H NMR(CDCl3,400 MHz):δ8.50-8.45(m,2H),8.02(dd,J1=8.0 Hz,J2=1.6 Hz,2H),7.97(d,J=8.8 Hz,1H),7.71-7.66(m,2H),7.62-7.53(m,4H),7.39-7.35(m,1H),7.32-7.28(m,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ158.7(d, 1 J C-F =251.3Hz),148.9,139.0(d, 4 J C-F =1.4 Hz),133.8,130.8(d, 4 J C-F =2.9 Hz),129.8,128.8(d, 3 J C-F =8.6 Hz),128.6,127.4,127.1(d, 3 J C-F =4.3 Hz),122.0,120.9,118.43,118.39,118.1(d,2 J C-F =16.6Hz),117.9,116.8,111.9(d, 2 J C-F =20.2 Hz),109.1(d, 3 J C-F =5.8 Hz). 19 F NMR(CDCl3,376MHz):δ-120.24(dd,J1=9.8 Hz,J2=5.6 Hz).HRMS(ESI)m / z:[M+H] + Calcd forC 21 H 14 FN2313.1136;Found 313.1139.

[0079] 2-Methoxy-6-phenylindazolo[3,2-a]isoquinoline and 4-methoxy-6-phenylindazolo[3,2-a]isoquinoline(3ka+3ka′)

[0080] 1 H NMR(DMSO-d6,600 MHz):δ8.61(d,J=8.4 Hz,1.5H),8.36(d,J=7.8 Hz,0.5H),8.03(d,J=2.4 Hz,1H),8.01(s,0.5H),7.99-7.97(m,3.5H),7.87(d,J=9.0Hz,1.5H),7.77(s,0.5H),7.74(t,J=7.8 Hz,0.5H),7.70(s,1H),7.62-7.54(m,6H),7.38-7.34(m,1.5H),7.32(dd,J1=9.0 Hz,J2=2.4 Hz,1H),7.19(d,J=8.4 Hz,0.5H),4.06(s,3H),4.00(s,1.5H). 13 C{ 1H}NMR(DMSO-d6,150 MHz):δ160.0,155.5,148.6,148.4,137.2,135.6,134.3,130.9,130.5,130.3,130.20,130.15,129.8,129.5,128.8,128.7,127.8,127.6,126.5,126.1,123.0,122.0,121.9,121.8,119.0,118.1,117.31,117.29,117.2,116.6,116.5,115.1,111.1,108.0,103.8,56.4,56.1.HRMS(ESI)m / z:[M+H] + Calcd forC 22 H 17 N2O 325.1335;Found 325.1328.

[0081] 1-Fluoro-6-phenylindazolo[3,2-a]isoquinoline(3la)

[0082] 1 H NMR(CDCl3,400 MHz):δ8.71(dd,J1=8.8 Hz,J2=0.8 Hz,1H),7.98-7.95(m,2H),7.92(d,J=8.8 Hz,1H),7.66(dd,J1=7.6 Hz,J2=0.4 Hz,1H),7.60-7.49(m,5H),7.45-7.40(m,2H),7.33-7.29(m,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ157.4(d, 1 J C-F =250.6Hz),149.4,139.4,133.9,130.8(d, 3 J C-F =5.1 Hz),129.8,129.7,129.0(d, 4 J C-F =2.9 Hz),128.5,127.7(d, 3 J C-F =8.7 Hz),127.4(d, 5 J C-F =1.4Hz),123.5(d, 4 J C-F =2.2 Hz),123.2,121.6(d,3 J C-F =5.8 Hz),117.5,117.2,116.4(d, 4 J C-F =2.9 Hz),114.8(d, 2 J C-F =16.6Hz),113.9(d, 2 J C-F =23.1 Hz). 19 F NMR(CDCl3,565 MHz):δ-107.03(dd,J1=12.4 Hz,J2=4.0 Hz).HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 14 FN2313.1136;Found 313.1132.

[0083] 2,3-Dimethyl-6-phenylindazolo[3,2-a]isoquinoline(3ma)

[0084] 1 H NMR(CDCl3,600 MHz):δ8.41(d,J=8.4 Hz,1H),8.35(s,1H),7.91(d,J=7.2Hz,2H),7.85(d,J=8.4 Hz,1H),7.51(s,1H),7.48(t,J=7.2 Hz,2H),7.45-7.41(m,2H),7.24-7.22(m,2H),2.46(s,3H),2.35(s,3H). 13 C{ 1 H}NMR(CDCl3,150 MHz):δ148.9,138.0,137.6,136.9,134.3,131.3,129.7,129.4,128.5,127.7,127.2,127.0,124.1,122.9,121.3,120.9,117.5,116.53,116.47,20.7,20.2.HRMS(ESI)m / z:[M+H] + Calcd forC 23 H 19 N2323.1543;Found 323.1538.

[0085] 2,3-Dimethoxy-6-phenylindazolo[3,2-a]isoquinoline(3na)

[0086] 1 H NMR(CDCl3,600 MHz):δ8.27(d,J=8.4 Hz,1H),7.92-7.90(m,3H),7.84(d,J=9.0 Hz,1H),7.48(t,J=7.2 Hz,2H),7.43(t,J=7.2 Hz,2H),7.24(s,1H),7.21(t,J=7.8Hz,1H),7.11(s,1H),4.07(s,3H),3.93(s,3H). 13 C{ 1 H}NMR(CDCl3,150MHz):δ149.5,148.6,147.9,135.7,133.2,130.1,128.6,128.3,127.4,126.0,122.7,119.7,119.6,119.4,116.3,115.1,114.8,106.4,102.0,55.1,55.0.HRMS(ESI)m / z:[M+H] + Calcd forC 23 H 19 N2O2355.1441;Found 355.1435.

[0087] 7-Phenylbenzo[g]indazolo[3,2-a]isoquinoline(3oa)

[0088] 1 H NMR(CDCl3,600 MHz):δ9.02(s,1H),8.55(d,J=8.4 Hz,1H),8.24(s,1H),8.07(d,J=8.4 Hz,1H),7.99-7.96(m,3H),7.93(d,J=7.8 Hz,1H),7.59-7.54(m,4H),7.52-7.50(m,2H),7.40(s,1H),7.37(t,J=7.8 Hz,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ148.7,138.5,134.0,132.8,132.2,130.8,129.8,129.5,128.5,128.3,128.1,127.1,127.0,126.8,126.5,126.4,124.0,122.3,121.4,121.1,118.3,117.6,117.0.HRMS(ESI)m / z:[M+H] + Calcd for C25 H 17 N2345.1386;Found 345.1387.6-(p-Tolyl)indazolo[3,2-a]isoquinoline(3ab)

[0089] 1 H NMR(CDCl3,400 MHz):δ8.71(d,J=8.4 Hz,1H),8.49(d,J=8.4 Hz,1H),7.96(d,J=8.8 Hz,1H),7.90-7.86(m,3H),7.72(t,J=7.2 Hz,1H),7.59(t,J=8.0 Hz,1H),7.52(t,J=7.2 Hz,1H),7.41-7.37(m,3H),7.33(t,J=7.6 Hz,1H),2.47(s,3H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ148.9,139.6,138.6,131.5,131.2,129.6,129.2,128.7,128.1,127.6,127.2,127.1,125.7,122.7,121.4,121.2,117.8,116.8,116.5,21.5.HRMS(ESI)m / z:[M+H] + Calcd for C 22 H 17 N2309.1386;Found 309.1385.

[0090] 6-(4-Methoxyphenyl)indazolo[3,2-a]isoquinoline(3ac)

[0091] 1 H NMR(CDCl3,400 MHz):δ8.57(d,J=8.4 Hz,1H),8.36(d,J=8.4 Hz,1H),7.88-7.84(m,3H),7.72(d,J=8.0 Hz,1H),7.60-7.56(m,1H),7.47-7.40(m,2H),7.26(s,1H),7.22(t,J=7.6 Hz,1H),6.99(d,J=8.8 Hz,2H),3.79(s,3H). 13 C{ 1H}NMR(CDCl3,100MHz):δ160.6,148.8,138.2,131.5,131.2,128.7,128.0,127.5,127.18,127.16,126.3,125.5,122.7,121.4,121.2,117.7,116.8,116.3,114.0,55.5.HRMS(ESI)m / z:[M+H] + Calcdfor C 22 H 17 N2O 325.1335;Found 325.1336.

[0092] 6-([1,1'-Biphenyl]-4-yl)indazolo[3,2-a]isoquinoline(3ad)

[0093] 1 H NMR(CDCl3,600 MHz):δ8.75(d,J=8.4 Hz,1H),8.52(d,J=8.4 Hz,1H),8.11(d,J=7.8 Hz,2H),7.99(d,J=8.4 Hz,1H),7.92(d,J=7.8 Hz,1H),7.80(d,J=7.8Hz,2H),7.77(t,J=7.8 Hz,1H),7.70(d,J=7.2 Hz,2H),7.63(t,J=7.8 Hz,1H),7.55(t,J=7.2 Hz,1H),7.51-7.48(m,3H),7.40(t,J=7.2 Hz,1H),7.37-7.35(m,1H). 13 C{ 1 H}NMR(CDCl3,150 MHz):δ148.9,142.4,140.7,138.2,132.9,131.6,130.1,128.9,128.7,128.3,127.72,127.67,127.31,127.25,125.8,122.8,121.5,121.2,117.8,116.9,116.8.HRMS(ESI)m / z:[M+H] + Calcd for C 27 H 19 N2371.1543;Found 371.1541.

[0094] 6-(4-Fluorophenyl)indazolo[3,2-a]isoquinoline(3ae)

[0095] 1 H NMR(CDCl3,400 MHz):δ8.69(d,J=8.0 Hz,1H),8.47(d,J=8.4 Hz,1H),8.00-7.93(m,3H),7.86(d,J=8.0 Hz,1H),7.73(t,J=7.6 Hz,1H),7.59(t,J=7.2Hz,1H),7.53(t,J=7.2 Hz,1H),7.38(s,1H),7.33(t,J=7.6 Hz,1H),7.27-7.23(m,2H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ163.5(d, 1 J C-F =247.8 Hz),148.9,137.4,131.8(d, 3 J C-F =8.7 Hz),131.5,130.1(d, 4 J C-F =3.6 Hz),128.5,128.3,127.6,127.3,125.7,122.7,121.6,121.2,117.7,116.8,115.6(d, 2 J C-F =21.7 Hz). 19 F NMR(CDCl3,376 MHz):δ-111.26–-111.33(m).HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 14 FN2313.1136;Found 313.1141

[0096] 6-(4-Chlorophenyl)indazolo[3,2-a]isoquinoline(3af)

[0097] 1 H NMR(CDCl3,400 MHz):δ8.73(d,J=8.4 Hz,1H),8.50(d,J=8.4 Hz,1H),7.97-7.94(m,3H),7.89(d,J=8.0 Hz,1H),7.77(t,J=7.6 Hz,1H),7.63(t,J=7.6Hz,1H),7.56-7.52(m,3H),7.42(s,1H),7.37-7.33(m,1H). 13 C{1 H}NMR(CDCl3,100 MHz):δ148.9,137.3,135.6,132.4,131.5,131.1,128.8,128.5,127.7,127.4,125.8,122.8,121.6,121.1,117.7,116.9,116.8.HRMS(ESI)m / z:[M+H] + Calcd forC 21 H 14 ClN2329.0840;Found329.0844.

[0098] 6-(4-(Trifluoromethyl)phenyl)indazolo[3,2-a]isoquinoline(3ag)

[0099] 1 H NMR(CDCl3,400 MHz):δ8.71(d,J=8.4 Hz,1H),8.47(d,J=8.4 Hz,1H),8.13(d,J=8.0 Hz,2H),7.94(d,J=8.8 Hz,1H),7.88(d,J=8.0 Hz,1H),7.82(d,J=8.4Hz,2H),7.76(t,J=8.0 Hz,1H),7.62(t,J=7.6 Hz,1H),7.54(t,J=7.6 Hz,1H),7.43(s,1H),7.35(t,J=8.0 Hz,1H). 13 C{ 1 H}NMR(CDCl3,150 MHz):δ148.9,137.5,136.8,131.5,131.4(q, 2 J C-F =31.8 Hz),130.1,128.7,128.3,127.8,127.5,127.4,125.9,125.5(q, 3 J C-F =3.3 Hz),124.1(q, 1 J C-F =270.2 Hz),122.7,121.7,121.1,117.6,117.4,116.7. 19 F NMR(CDCl3,376 MHz):δ-62.71(s).HRMS(ESI)m / z:[M+H] + Calcd for C 22 H 14F3N2363.1104;Found363.1106.

[0100] 6-(m-Tolyl)indazolo[3,2-a]isoquinoline(3ah)

[0101] 1 H NMR(CDCl3,400 MHz):δ8.68(d,J=8.0 Hz,1H),8.46(d,J=8.4 Hz,1H),7.96(d,J=8.8 Hz,1H),7.83(d,J=8.0 Hz,1H),7.770-7.768(m,2H),7.69(t,J=8.0 Hz,1H),7.56(t,J=7.6 Hz,1H),7.51(t,J=7.6 Hz,1H),7.45(t,J=7.6 Hz,1H),7.38(s,1H),7.34-7.30(m,2H),2.47(s,3H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ148.9,138.7,138.2,134.0,131.5,130.4,130.3,128.7,128.4,128.1,127.6,127.2,127.1,126.9,125.7,122.7,121.4,121.2,117.8,116.81,116.79,21.7.HRMS(ESI)m / z:[M+H] + Calcd forC 22 H 17 N2309.1386;Found 309.1387.

[0102] 6-(3-Methoxyphenyl)indazolo[3,2-a]isoquinoline(3ai)

[0103] 1 H NMR(CDCl3,400 MHz):δ8.71(d,J=8.0 Hz,1H),8.49(d,J=8.4 Hz,1H),7.97(d,J=8.8 Hz,1H),7.87(d,J=8.0 Hz,1H),7.75-7.71(m,1H),7.61-7.46(m,5H),7.43(s,1H),7.34(t,J=7.6 Hz,1H),7.08(dd,J1=8.0 Hz,J2=1.2 Hz,1H),3.89(s,3H). 13 C{ 1H}NMR(CDCl3,150 MHz):δ159.6,148.9,138.3,135.3,131.5,129.6,128.6,128.3,127.7,127.24,127.19,125.7,122.7,122.2,121.5,121.1,117.8,116.9,116.8,115.39,115.35,55.5.HRMS(ESI)m / z:[M+H] + Calcd for C 22 H 17 N2O 325.1335;Found 325.1337.

[0104] 6-(3-Chlorophenyl)indazolo[3,2-a]isoquinoline(3aj)

[0105] 1 H NMR(CDCl3,400 MHz):δ8.71(d,J=8.0 Hz,1H),8.48(d,J=8.4 Hz,1H),8.00(s,1H),7.96(d,J=8.4 Hz,1H),7.91-7.88(m,2H),7.76(t,J=7.2 Hz,1H),7.62(t,J=7.6 Hz,1H),7.56-7.50(m,3H),7.43(s,1H),7.35(t,J=7.6 Hz,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ148.9,137.0,135.7,134.4,131.5,129.81,129.76,129.7,128.6,128.4,128.0,127.8,127.4,125.9,122.7,121.6,121.1,117.7,117.2,116.7.HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 14 ClN2329.0840;Found 329.0838.

[0106] 6-(o-Tolyl)indazolo[3,2-a]isoquinoline(3ak)

[0107] 1H NMR(CDCl3,600 MHz):δ8.76(d,J=7.8 Hz,1H),8.51(d,J=8.4 Hz,1H),7.94(d,J=8.4 Hz,1H),7.88(d,J=7.8 Hz,1H),7.76(t,J=7.2 Hz,1H),7.62(t,J=7.2Hz,1H),7.52-7.49(m,2H),7.47(t,J=7.8 Hz,1H),7.40-7.32(m,4H),2.14(s,3H). 13 C{ 1 H}NMR(CDCl3,150 MHz):δ149.3,138.7,138.2,134.2,131.0,130.34,130.27,129.7,128.4,128.3,127.6,127.2,127.1,126.1,125.9,122.8,121.5,121.2,118.0,117.1,116.8,19.8.HRMS(ESI)m / z:[M+H] + Calcd for C 22 H 17 N2309.1386;Found 309.1390.

[0108] 6-(2-Bromophenyl)indazolo[3,2-a]isoquinoline(3al)

[0109] 1 H NMR(CDCl3,600 MHz):δ8.76(d,J=7.8 Hz,1H),8.51(d,J=9.0 Hz,1H),7.94(d,J=9.0 Hz,1H),7.90(d,J=7.8 Hz,1H),7.80-7.77(m,2H),7.64-7.60(m,2H),7.52-7.50(m,2H),7.42(td,J1=7.8 Hz,J2=1.8 Hz,1H),7.39(s,1H),7.34(t,J=7.2Hz,1H). 13 C{ 1H}NMR(CDCl3,150 MHz):δ149.1,137.2,135.6,133.2,132.0,131.0,130.9,128.6,128.2,127.9,127.7,127.2,127.1,126.1,124.6,122.9,121.5,121.1,117.9,117.7,116.8.HRMS(ESI)m / z:[M+H] + Calcd for C 21 H 14 BrN2373.0335;Found 373.0338.

[0110] 6-(3,4,5-Trimethoxyphenyl)indazolo[3,2-a]isoquinoline(3am)

[0111] 1 H NMR(CDCl3,600 MHz):δ8.63(d,J=7.8 Hz,1H),8.40(d,J=8.4 Hz,1H),7.89(d,J=8.4 Hz,1H),7.80(d,J=7.2 Hz,1H),7.66-7.64(m,1H),7.53(t,J=7.2 Hz,1H),7.45-7.44(m,1H),7.34(s,1H),7.26-7.24(m,1H),7.16(s,2H),3.88(s,3H),3.85(s,6H). 13 C{ 1 H}NMR(CDCl3,150 MHz):δ153.3,148.9,139.2,138.3,131.6,129.3,128.6,128.3,127.6,127.34,127.28,125.6,122.7,121.5,121.2,117.8,116.7,107.3,60.9,56.4.HRMS(ESI)m / z:[M+H] + Calcd for C 24 H 21 N2O3385.1547;Found385.1544.

[0112] 6-(Benzo[d][1,3]dioxol-5-yl)indazolo[3,2-a]isoquinoline(3an)

[0113] 1H NMR(CDCl3,400 MHz):δ8.71(d,J=8.0 Hz,1H),8.49(d,J=8.8 Hz,1H),7.97(d,J=8.8 Hz,1H),7.87(d,J=7.6 Hz,1H),7.75-7.71(m,1H),7.62-7.52(m,3H),7.43(dd,J1=8.4 Hz,J2=2.0 Hz,1H),7.40(s,1H),7.34(t,J=7.6 Hz,1H),7.00(d,J=8.0Hz,1H),6.08(s,2H). 13 C{ 1 H}NMR(CDCl3,150 MHz):δ148.9,148.8,147.6,138.1,131.5,128.6,128.1,127.7,127.6,127.24,127.22,125.6,123.9,122.7,121.5,121.2,117.7,116.8,116.5,110.4,108.5,101.5.HRMS(ESI)m / z:[M+H] + Calcd for C 22 H 15 N2O2339.1128;Found 339.1127.

[0114] 6-(Naphthalen-2-yl)indazolo[3,2-a]isoquinoline(3ao)

[0115] 1 H NMR(CDCl3,600MHz):δ8.70(d,J=8.4Hz,1H),8.48(d,J=8.4Hz,1H),8.40(s,1H),8.10(dd,J1=8.4Hz,J2=1.2Hz,1H),8.00(d,J=8.4Hz,1H),7.96-7.91(m,3H),7.87(d,J=7.8Hz,1H),7.72(t,J=7.2Hz,1H),7.58(t,J=7.2Hz,1H),7.56-7.50(m,4H),7.33(t,J=7.8Hz,1H). 13 C{ 11H NMR(CDCl3, 150 MHz): δ 149.0, 138.5, 133.9, 133.4, 131.7, 131.5, 129.2, 128.7, 128.6, 128.3, 127.9, 127.8, 127.7, 127.27, 127.25, 127.1, 127.0, 126.4, 125.8, 122.8, 121.5, 121.2, 117.8, 117.2, 116.8. HRMS(ESI) m / z: [M + H] + Calcd for C 25 H 17 N2 345.1386; Found 345.1374. 6 - Cyclohexylindazolo[3,2 - a]isoquinoline(3ap)

[0116] 1 1H NMR(CDCl3, 400 MHz): δ 8.70(d, J = 8.0 Hz, 1H), 8.49(d, J = 8.4 Hz, 1H), 8.01(d, J = 8.8 Hz, 1H), 7.86(d, J = 7.6 Hz, 1H), 7.70(td, J1 = 7.2 Hz, J2 = 1.2 Hz, 1H), 7.62 - 7.54(m, 2H), 7.35 - 7.31(m, 1H), 7.26(s, 1H), 3.94(tt, J1 = 11.6 Hz, J2 = 3.2 Hz, 1H), 2.36(d, J = 11.6 Hz, 2H), 1.97 - 1.88(m, 3H), 1.75 - 1.52(m, 4H), 1.44 - 1.37(m, 1H). 13 C{ 1 1H NMR(CDCl3, 150 MHz): δ 148.7, 144.7, 131.0, 128.7, 127.4, 127.2, 127.1, 127.0, 125.0, 122.6, 121.3, 121.1, 117.3, 116.9, 111.7, 38.3, 31.8, 26.6, 26.5. HRMS(ESI) m / z: [M + H] + Calcd for C 21 H 21 N2 301.1699; Found 301.1696.

[0117] Example 4

[0118]

[0119] Compound 1a, organic solvent, catalyst, additive and 4a were added to a 15 mL reaction tube in sequence, the reaction tube was sealed, and the mixture was placed in an oil bath and heated and stirred for reaction. After the reaction was completed, the mixture was cooled to room temperature, water was added to quench the reaction, and the mixture was extracted with dichloromethane. The organic phase was dried, filtered, and the filtrate was concentrated and separated by a silica gel column (petroleum ether / dichloromethane = 2:1) to obtain a yellow solid product 5aa.

[0120] By changing the reaction conditions such as the catalyst, additives, organic solvent and the amount of each substance, the reaction results are shown in Table 2.

[0121] Table 2 Synthesis of 5aa under different conditions a

[0122]

[0123] Example 5

[0124]

[0125] 1a (19.4 mg, 0.1 mmol), trifluoroethanol (1 mL), [RhCp*Cl2]2 (1.2 mg, 0.002 mmol), silver acetate (2.7 mg, 0.016 mmol) and 4a (39.5 mg, 0.15 mmol) were added to a 15 mL pressure tube in sequence, and then the reaction tube was sealed and placed in a 120 ° C oil bath for 12 h. After the reaction, the reaction system was cooled to room temperature, water was added to quench the reaction, and then dichloromethane was extracted three times, the organic phases were combined, dried over anhydrous sodium sulfate, filtered through diatomaceous earth, the filtrate was concentrated, and separated by a silica gel column (petroleum ether / dichloromethane = 2:1) to obtain a yellow solid product 5aa (23 mg, 61%). The characterization data of this compound are: 1 HNMR (CDCl3, 400MHz): δ8.08(d,J=8.4Hz,1H),8.01(d,J=8.0Hz,1H),7.85(d,J=8.8Hz,1H),7.42-7.38(m,2H),7.29-7.27(m,2H),7.26-7 .21(m,1H),7.18-7.14(m,2H),7.05(t,J=7.2Hz,1H),6.98(d,J=7.6Hz,2H),5.63(s,1H),3.75(d,J=16.8Hz,1H),3.52(d,J=16.8Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,150MHz): δ148.7,142.5,131.9,129.7,129.3,129.1,128.9,128.5,127.5,126.2,124.6(q,1 J C-F =287.7Hz),123.9,121.7,121.6,120.6,118.9,118.5,76.8(q, 2 J C-F =28.5Hz),33.4. 19 FNMR(CDCl3,376MHz):δ-79.14(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 16 F3N3Na 402.1189;Found 402.1176.

[0126] Example 6

[0127] According to the method and steps of Example 5 a,b By changing reactant 1 and reactant 4, various indazole [3,2-a] isoquinoline compounds 5 were synthesized. The specific results are as follows:

[0128]

[0129] a Reaction conditions: 1 (0.1 mmol), 4 (0.15 mmol), [RhCp*Cl2]2 (0.002 mmol), silver acetate (0.016 mmol), trifluoroethanol (1 mL), 120 °C, 12 h, air atmosphere; b Isolated yield.

[0130] The characterization data of representative products are as follows: 3-Ethyl-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ba)

[0131] 1 H NMR (CDCl3, 400MHz): δ7.97(d,J=8.4Hz,1H),7.83(d,J=8.4Hz,1H),7.75(d,J=8.8Hz,1H),7.31-7.27(m,1H),7.15-7.02(m,5H),6.95(t,J= 7.2Hz, 1H), 6.89 (d, J = 7.6Hz, 2H), 5.55 (s, 1H), 3.64 (d, J = 16.8Hz, 1H), 3.40 (d, J = 17.2Hz, 1H), 2.57 (q, J = 7.6Hz, 2H), 1.16 (t, J = 7.2Hz, 3H). 13 C{1 H}NMR(DMSO-d6,150MHz):δ148.6,144.8,142.5,132.1,129.7,129.0,128.6,127.8,127.4,124.5(q, 1 J C-F =294.3Hz),123.9,123.8,123.6,121.7,121.5,120.5,118.8,118.3,76.7(q, 2 J C-F =28.5Hz),33.4,28.5,15.7. 19 F NMR(CDCl3,376MHz):δ-79.26(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 24 H 20 F3N3Na 430.1502;Found 430.1503.

[0132] N,3-Diphenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ca)

[0133] 1 H NMR(CDCl3,600MHz):δ8.03(d,J=8.4Hz,1H),7.99(d,J=7.8Hz,1H),7.79(d,J=8.4Hz,1H),7.55-7.54(m,3H),7.44(s,1H),7.40-7.37(m,2H),7.34-7.29(m,2H),7.18-7.16(m,1H),7.09(t,J=7.8Hz,2H),6.98(t,J=7.2Hz,1H),6.93(d,J=7.8Hz,2H),5.57(s,1H),3.73(d,J=16.8Hz,1H),3.52(d,J=16.8Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,100MHz):δ148.7,142.5,140.3,139.6,131.7,130.5,129.5,129.1,128.4,127.51,127.48,127.0,126.5,125.2,124.6(q, 1 J C-F=286.8Hz),124.4,123.9,121.7,121.6,120.6,118.9,118.6,76.9(q, 2 J C-F =28.9Hz),33.5. 19 FNMR(CDCl3,376MHz):δ-79.23(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 28 H 20 F3N3Na 478.1502;Found 478.1501.

[0134] 3-Fluoro-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5da)

[0135] 1 H NMR(CDCl3,600MHz):δ8.00(d,J=9.0Hz,1H),7.96(dd,J1=9.0Hz,J2=5.4Hz,1H),7.84(d,J=8.4Hz,1H),7.40-7.38(m,1H),7.23-7.21(m,1H),7.17-7.15(m,2H),7.10-7.05(m,2H),7.01(d,J=9.0Hz,1H),6.98(d,J=7.8Hz,2H),5.62(s,1H),3.72(d,J=16.8Hz,1H),3.49(d,J=16.8Hz,1H). 13 C{ 1 H}NMR(CDCl3,150MHz):δ162.1(d, 1 J C-F =248.4Hz),148.9,140.1,131.5(d, 3 J C-F =7.7Hz),131.4,129.1,127.1,126.1,125.4,125.2(d, 3 J C-F =8.7Hz),123.8(q, 1 J C-F =286.5 Hz),123.5,123.1(d, 4 J C-F =3.3 Hz),120.6,118.9,118.7,115.6(d, 2 JC-F =23.1Hz),115.0(d, 2 J C-F =21.9 Hz),77.0(q, 2 J C-F =28.4Hz),33.3. 19 F NMR(CDCl3,565MHz):δ-79.35(s),-111.77–-111.81(m).HRMS(ESI)m / z:[M+Na] + Calcd forC 22 H 15 F4N3Na 420.1094;Found 420.1098

[0136] 3-Bromo-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5fa)

[0137] 1 H NMR(DMSO-d6,400 MHz):δ8.22(d,J=8.8 Hz,1H),8.09(d,J=8.4 Hz,1H),7.78-7.75(m,2H),7.63(dd,J1=8.4 Hz,J2=2.0 Hz,1H),7.42-7.38(m,1H),7.28-7.25(m,1H),7.09(s,1H),7.04-7.00(m,2H),6.77(t,J=7.6 Hz,1H),6.60(d,J=8.0 Hz,2H),4.04(d,J=17.6 Hz,1H),3.75(d,J=17.6 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,100 MHz):δ148.6,142.4,132.3,132.0,131.2,131.1,129.1,127.6,124.4(q, 1 J C-F =287.5 Hz),125.7,125.4,124.1,121.6,121.5,120.4,119.0,118.6,76.7(q, 2 J C-F =28.9 Hz),33.1. 19 F NMR(CDCl3,376 MHz):δ-79.32(s).HRMS(ESI)m / z:[M+Na] +Calcd for C 22 H 15 BrF3N3Na480.0294;Found 480.0297.N-Phenyl-3,6-bis(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ga)

[0138] 1 H NMR(DMSO-d6,600 MHz):δ8.34(d,J=8.4 Hz,1H),8.28(d,J=8.4 Hz,1H),7.91(s,1H),7.82(d,J=9.0 Hz,1H),7.77(d,J=7.8 Hz,1H),7.45-7.42(m,1H),7.34-7.31(m,1H),7.12(s,1H),7.02(t,J=8.4 Hz,2H),6.78(t,J=7.2 Hz,1H),6.62(d,J=8.4Hz,2H),4.13(d,J=17.4 Hz,1H),3.88(d,J=18.0 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,150MHz):δ148.7,142.2,131.0,130.6,129.8,129.1,128.4(q, 2 J C-F =31.7 Hz),127.7,126.1(q, 3 J C-F =3.3 Hz),125.2(q, 3 J C-F =4.4 Hz),124.7,124.5(q, 1 J C-F =270.2 Hz),124.4(q, 1 J C-F =287.7 Hz),124.3,121.8,121.4,120.8,119.14,119.12,77.0(q, 2 J C-F =28.5 Hz),33.3. 19 F NMR(CDCl3,565 MHz):δ-62.69(s),-79.32(s).HRMS(ESI)m / z:[M+Na] + Calcd forC 23 H 15F6N3Na 470.1062;Found470.1061.

[0139] 6-(Phenylamino)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinoline-3-carbonitrile(5ha)

[0140] 1 H NMR(CDCl3,600 MHz):δ7.96-7.92(m,2H),7.81(d,J=9.0 Hz,1H),7.57(d,J=8.4 Hz,1H),7.47(s,1H),7.35(d,J=8.4 Hz,1H),7.22(t,J=7.8 Hz,1H),7.09(t,J=7.8Hz,2H),7.00(t,J=7.8 Hz,1H),6.90(d,J=8.4 Hz,2H),5.54(s,1H),3.64(d,J=16.8Hz,1H),3.47(d,J=17.4 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,100 MHz):δ148.7,142.1,132.8,132.3,131.0,130.4,130.2,129.1,127.8,124.9,124.337(q, 1 J C-F =286.7 Hz),124.340,121.9,121.4,120.9,119.3,119.2,119.0,110.4,77.0(q, 2 J C-F =28.9 Hz),33.1. 19 F NMR(CDCl3,565 MHz):δ-79.28(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 23 H 15 F3N4Na 427.1141;Found 427.1139.

[0141] 4-Fluoro-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ja)

[0142] 1H NMR(DMSO-d6,600 MHz):δ8.24(d,J=8.4 Hz,1H),8.00(d,J=7.8 Hz,1H),7.78(d,J=8.4 Hz,1H),7.53-7.49(m,1H),7.42-7.39(m,1H),7.29-7.25(m,2H),7.12(s,1H),7.02-6.99(m,2H),6.77(t,J=7.2 Hz,1H),6.59(d,J=7.8 Hz,2H),3.98(d,J=17.4Hz,1H),3.67(d,J=17.4 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,100MHz):δ160.1(d, 1 J C-F =243.4Hz),148.6,142.3,131.0(d, 4 J C-F =2.9 Hz),130.2(d, 3 J C-F =8.7 Hz),129.0,128.2(d, 3 J C-F =4.3 Hz),127.6,124.4(q, 1 J C-F =289.0 Hz),124.3,121.8,121.4,120.6,120.0(d, 4 J C-F =2.1 Hz),119.0,118.7,116.3(d, 2 J C-F =17.3 Hz),115.6(d, 2 J C-F =21.0 Hz),76.6(q, 2 J C-F =28.2 Hz),27.0. 19 F NMR(DMSO-d6,376 MHz):δ-76.46(s),-117.54(dd,J1=9.8 Hz,J2=5.6 Hz).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 F4N3Na 420.1094;Found 420.1101.

[0143] 2-Methoxy-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine and 4-methoxy-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ka+5ka′)

[0144] 1 H NMR(DMSO-d6,400 MHz):δ8.24-8.22(m,1.8H),7.81-7.72(m,2.6H),7.56(d,J=2.4 Hz,1H),7.46(t,J=8.0 Hz,1H),7.41-7.36(m,2.8H),7.27-7.22(m,1.8H),7.17(s,0.8H),7.07(d,J=8.0 Hz,1H),7.04-7.00(m,4.2H),6.96(dd,J1=8.4 Hz,J2=2.4 Hz,1H),6.78-6.75(m,1.8H),6.62(d,J=8.0 Hz,2H),6.57(d,J=8.0 Hz,1.6H),3.93(d,J=17.6 Hz,0.8H),3.89(s,3H),3.87(s,2.4H),3.83(d,J=18.8 Hz,1H),3.65(d,J=8.8 Hz,1H),3.60(d,J=8.4 Hz,0.8H). 13 C{ 1 H}NMR(DMSO-d6,150 MHz):δ159.3,156.7,148.8,148.6,142.6,142.4,131.7,130.4,129.5,129.1,129.0,127.5,127.4,127.1,126.9,124.5(q, 1 J C-F =288.8 Hz),124.0,123.9,121.7,121.62,121.57,121.5,120.50,120.46,118.9,118.8,118.5,116.9,116.3,114.6,111.4,109.0,76.9(q, 2 J C-F =28.5 Hz),76.6(q, 2 J C-F=29.6 Hz),56.2,55.8,32.8,27.0. 19 FNMR(DMSO-d6,376 MHz):δ-76.40(s),-77.41(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 23 H 18 F3N3NaO432.1294;Found 432.1297.

[0145] 1-Fluoro-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5la)

[0146] 1 H NMR(DMSO-d6,400 MHz):δ8.05(dd,J1=8.8 Hz,J2=4.0 Hz,1H),7.80(d,J=8.8 Hz,1H),7.46-7.33(m,4H),7.25-7.21(m,1H),7.03-6.98(m,3H),6.78(t,J=7.2Hz,1H),6.59(d,J=7.6 Hz,2H),3.99(d,J=17.2 Hz,1H),3.75(d,J=17.2 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,100 MHz):δ157.1(d, 1 J C-F =247.1 Hz),148.6,142.6,132.6(d, 4 J C-F =4.3Hz),130.7(d, 3 J C-F =8.7 Hz),129.0,128.0,127.5,125.8(d, 5 J C-F =2.2 Hz),124.5(q, 1 J C-F =287.5 Hz),123.7(d, 4 J C-F =4.3 Hz),122.7(d, 2 J C-F =21.6Hz),121.8,120.5,119.2,118.8,115.9(d, 2 J C-F=21.7 Hz),114.4(d, 3 J C-F =15.9 Hz),77.1(q, 2 J C-F =29.6 Hz),34.7. 19 F NMR(DMSO-d6,376 MHz):δ-75.35(s),-111.11–-111.17(m).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 F4N3Na 420.1094;Found420.1110.

[0147] 2,3-Dimethyl-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ma)

[0148] 1 H NMR(DMSO-d6,600 MHz):δ8.30(d,J=8.4 Hz,1H),7.92(s,1H),7.71(d,J=9.0Hz,1H),7.38-7.35(m,1H),7.24-7.21(m,2H),7.06(s,1H),7.02(t,J=7.2 Hz,2H),6.76(t,J=7.2 Hz,1H),6.62-6.60(m,2H),3.93(d,J=17.4 Hz,1H),3.58(d,J=17.4 Hz,1H),2.35(s,3H),2.26(s,3H). 13 C{ 1 H}NMR(DMSO-d6,150 MHz):δ148.6,142.6,137.5,136.6,132.1,130.2,129.0,127.4,127.0,124.7,124.6(q, 1 J C-F =287.7 Hz),123.8,123.4,122.0,121.4,120.2,118.7,118.2,76.7(q, 2 J C-F =28.5 Hz),32.9,19.8,19.5. 19 F NMR(CDCl3,376 MHz):δ-79.28(s).HRMS(ESI)m / z:[M+Na] +Calcd for C 24 H 20 F3N3Na 430.1502;Found 430.1508.

[0149] 2,3-Dimethoxy-N-phenyl-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5na)

[0150] 1 H NMR(CDCl3,600 MHz):δ8.00(d,J=8.4 Hz,1H),7.83(d,J=8.4 Hz,1H),7.50(s,1H),7.38(t,J=6.6 Hz,1H),7.21(t,J=7.8 Hz,1H),7.16(t,J=7.8 Hz,2H),7.05(t,J=7.2 Hz,1H),6.98(d,J=7.8 Hz,2H),6.78(s,1H),5.62(s,1H),4.01(s,3H),3.92(s,3H),3.71(d,J=16.8 Hz,1H),3.45(d,J=16.8 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,150 MHz):δ149.5,148.8,148.6,142.6,132.2,129.0,127.4,124.6(q, 1 J C-F =287.7 Hz),123.3,122.5,121.8,121.4,120.3,118.7,118.6,117.8,112.9,107.3,76.6(q, 2 J C-F =28.5 Hz),56.3,56.1,33.0. 19 F NMR(CDCl3,565 MHz):δ-79.37(s).HRMS(ESI)m / z:[M+Na] + Calcd forC 24 H 20 F3N3NaO2462.1400;Found 462.1392.N-Phenyl-7-(trifluoromethyl)-7,8-dihydrobenzo[g]indazolo[3,2-a]isoquinolin-7-amine(5oa)

[0151] 1 H NMR(CDCl3,600 MHz):δ8.42(s,1H),8.24(d,J=8.4 Hz,1H),7.91-7.88(m,2H),7.77-7.75(m,1H),7.73(s,1H),7.50-7.46(m,2H),7.43(t,J=6.6 Hz,1H),7.30(t,J=7.8 Hz,1H),7.18(t,J=8.4 Hz,2H),7.07-7.05(m,3H),5.72(s,1H),3.83(d,J=16.8Hz,1H),3.69(d,J=16.8 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,100 MHz):δ148.6,142.5,133.1,132.8,132.1,129.1,128.9,127.8,127.7,127.6,127.5,127.0,124.6(q, 1 J C-F =285.3Hz),124.4,124.0,122.9,122.0,121.7,120.7,118.9,118.8,77.0(q, 2 J C-F =28.9 Hz),34.1. 19 F NMR(DMSO-d6,565 MHz):δ-76.04(s).HRMS(ESI)m / z:[M+Na] + Calcd forC 26 H 18 F3N3Na 452.1345;Found 452.1347.

[0152] N-(4-Ethylphenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ab)

[0153] 1H NMR(CDCl3,600 MHz):δ8.07(d,J=8.4 Hz,1H),7.99(d,J=7.2 Hz,1H),7.86(d,J=9.0 Hz,1H),7.40-7.36(m,2H),7.28-7.21(m,3H),6.98(d,J=8.4 Hz,2H),6.94(d,J=8.4 Hz,2H),5.56(s,1H),3.69(d,J=16.8 Hz,1H),3.48(d,J=16.8 Hz,1H),2.52(q,J=7.2 Hz,2H),1.13(t,J=7.8 Hz,3H). 13 C{ 1 H}NMR(CDCl3,150 MHz):δ148.8,141.7,137.7,132.2,129.0,128.4,128.2,128.1,127.8,126.9,126.74,126.68,123.9(q, 1 J C-F =286.7 Hz),123.4,123.3,120.9,119.0,118.9,77.5(d, 2 J C-F =28.4 Hz),33.3,28.2,15.5. 19 F NMR(CDCl3,565 MHz):δ-79.24(s).HRMS(ESI)m / z:[M+Na] + Calcd forC 24 H 20 F3N3Na 430.1502;Found 430.1505.N-(4-Chlorophenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ac)

[0154] 1 H NMR(CDCl3,400 MHz):δ8.07(d,J=8.4 Hz,1H),8.00(d,J=7.6 Hz,1H),7.83(d,J=8.8 Hz,1H),7.41-7.38(m,2H),7.29-7.22(m,3H),7.12(d,J=8.0 Hz,2H),6.91(d,J=8.4 Hz,2H),5.59(s,1H),3.68(d,J=16.8 Hz,1H),3.50(d,J=16.8 Hz,1H). 13 C{1 H}NMR(DMSO-d6,150 MHz):δ148.7,141.7,132.0,129.6,129.3,128.94,128.88,128.5,127.6,126.1,125.2,124.5(q, 1 J C-F =286.7 Hz),123.9,121.7,121.4,118.9,118.5,76.6(q, 2 J C-F =28.5 Hz),33.5. 19 F NMR(CDCl3,376 MHz):δ-79.18(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 ClF3N3Na 436.0799;Found436.0792.

[0155] N-(4-Nitrophenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ae)

[0156] 1 H NMR(CDCl3,400 MHz):δ8.11-8.06(m,2H),7.97(d,J=9.2 Hz,2H),7.75(d,J=8.8 Hz,1H),7.49-7.45(m,1H),7.39(t,J=7.2 Hz,1H),7.35-7.34(m,2H),7.25(t,J=8.0Hz,1H),6.69(d,J=8.8 Hz,2H),6.12(s,1H),4.06(d,J=17.6 Hz,1H),3.72(d,J=17.2Hz,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ149.3,147.4,142.0,132.0,128.8,128.5,128.4,127.9,127.6,126.3,125.3,124.0,123.9,123.7(q, 1 J C-F =288.2Hz),120.9,118.9,118.8,118.7,75.9(q, 2 J C-F =30.3 Hz),33.3.19 F NMR(CDCl3,565MHz):δ-78.76(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 F3N4NaO2447.1039;Found 447.1040.

[0157] N-(3-Chlorophenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5af)

[0158] 1 H NMR(CDCl3,400 MHz):δ8.06(d,J=8.4 Hz,1H),8.00(d,J=7.6 Hz,1H),7.84(d,J=8.8 Hz,1H),7.41-7.37(m,2H),7.30-7.27(m,2H),7.24-7.20(m,1H),7.06-6.99(m,3H),6.80-6.77(m,1H),5.68(s,1H),3.73(d,J=16.8 Hz,1H),3.54(d,J=16.8 Hz,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ149.0,141.8,134.5,132.1,130.0,128.5,128.4,128.3,128.1,127.2,126.6,125.7,125.1,123.8(q, 1 J C-F =287.5 Hz),123.6,123.5,123.3,120.9,119.0,118.9,76.9(q, 2 J C-F =27.4 Hz),33.3. 19 F NMR(CDCl3,376 MHz):δ-79.11(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 ClF3N3Na 436.0799;Found 436.0794.

[0159] N-(3-Bromophenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ag)

[0160] 1 H NMR(CDCl3,400 MHz):δ8.07(d,J=8.8 Hz,1H),8.01(d,J=8.0 Hz,1H),7.83(d,J=8.8 Hz,1H),7.42-7.37(m,2H),7.32-7.21(m,4H),7.18-7.16(m,1H),6.99(t,J=8.0 Hz,1H),6.83(dd,J1=8.0 Hz,J2=1.2 Hz,1H),5.65(s,1H),3.72(d,J=17.2Hz,1H),3.55(d,J=16.8 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,150 MHz):δ148.7,144.8,132.0,130.8,129.5,129.0,128.5,127.6,126.1,124.5(q, 1 J C-F =287.7 Hz),123.98,123.97,123.4,122.0,121.7,121.6,118.8,118.4,117.5,76.4(q, 2 J C-F =29.4Hz),34.1. 19 F NMR(CDCl3,376 MHz):δ-79.13(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 BrF3N3Na 480.0294;Found480.0295.

[0161] 6-(Trifluoromethyl)-N-(3-(trifluoromethyl)phenyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ah)

[0162] 1H NMR(CDCl3,600 MHz):δ8.07(d,J=8.4 Hz,1H),8.01(d,J=7.8 Hz,1H),7.83(d,J=9.0 Hz,1H),7.42-7.39(m,2H),7.32-7.27(m,4H),7.25-7.21(m,2H),7.01(d,J=7.8 Hz,1H),5.68(s,1H),3.72(d,J=16.2 Hz,1H),3.60(d,J=16.8 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,150 MHz):δ148.6,143.9,132.0,130.1,129.8(q, 2 J C-F =30.6 Hz),129.6,129.4,129.0,128.6,127.7,126.1,124.49(q, 1 J C-F =288.8 Hz),124.48(q, 1 J C-F =271.2 Hz),124.01,123.99,121.7,121.5,118.8,118.3,116.8(q, 3 J C-F =3.3 Hz),115.1(q, 3 J C-F =3.3Hz),76.4(q, 2 J C-F =29.6 Hz),34.4. 19 F NMR(CDCl3,565 MHz):δ-62.81(s),-79.00(s).HRMS(ESI)m / z:[M+Na] + Calcd forC 23 H 15 F6N3Na 470.1062;Found 470.1063.

[0163] N-(o-Tolyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ai)

[0164] 1H NMR(CDCl3,400 MHz):δ8.09(d,J=8.8 Hz,1H),8.02(d,J=7.6 Hz,1H),7.85(d,J=8.8 Hz,1H),7.41-7.36(m,2H),7.26-7.21(m,3H),7.17(d,J=7.2 Hz,1H),6.96(td,J1=7.6 Hz,J2=0.8 Hz,1H),6.87-6.83(m,1H),6.55(d,J=7.6 Hz,1H),5.27(s,1H),3.71(d,J=17.2 Hz,1H),3.43(d,J=17.2 Hz,1H),2.39(s,3H). 13 C{ 1 H}NMR(CDCl3,150MHz):δ149.0,138.8,135.2,132.1,130.9,129.0,128.21,128.19,127.9,127.0,126.7,126.6,125.3,124.9,124.1(q, 1 J C-F =286.7 Hz),123.5,123.4,121.0,119.1,119.0,77.5(q, 2 J C-F =28.4 Hz),32.0,18.2. 19 F NMR(CDCl3,376MHz):δ-79.63(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 23 H 18 F3N3Na 416.1345;Found 416.1340.

[0165] N-(2-Methoxyphenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5aj)

[0166] 1H NMR(DMSO-d6,600 MHz):δ8.24(d,J=8.4 Hz,1H),8.10(d,J=7.8 Hz,1H),7.77(d,J=9.0 Hz,1H),7.47(d,J=7.8 Hz,1H),7.43(t,J=7.2 Hz,1H),7.41-7.38(m,1H),7.36-7.33(m,1H),7.25-7.23(m,1H),6.83-6.80(m,2H),6.58-6.55(m,1H),6.52-6.51(m,1H),5.81(s,1H),3.97(d,J=16.8 Hz,1H),3.84(d,J=17.4 Hz,1H),3.62(s,3H). 13 C{ 1 H}NMR(DMSO-d6,150 MHz):δ151.7,148.7,131.9,130.7,129.2,128.9,128.4,127.5,126.1,124.6(q, 1 J C-F =287.7 Hz),123.80,123.79,123.4,121.6,121.0,120.7,118.8,118.3,111.5,77.0(q, 2 J C-F =28.5 Hz),56.0,33.8. 19 FNMR(CDCl3,565 MHz):δ-78.90(s).HRMS(ESI)m / z:[M+Na] + Calcd forC 23 H 18 F3N3NaO 432.1294;Found 432.1298.

[0167] N-(2-Fluorophenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5ak)

[0168] 1H NMR(CDCl3,400 MHz):δ7.99(d,J=8.8 Hz,1H),7.92(d,J=8.0 Hz,1H),7.76(d,J=8.8 Hz,1H),7.33-7.29(m,2H),7.23-7.19(m,2H),7.17-7.13(m,1H),6.97-6.86(m,2H),6.75-6.67(m,2H),5.38(s,1H),3.67(d,J=17.2 Hz,1H),3.58(d,J=16.8 Hz,1H). 13 C{ 1 H}NMR(CDCl3,100 MHz):δ157.3(d, 1 J C-F =244.1 Hz),149.0,132.1,128.6,128.5,128.3(d, 3 J C-F =5.8 Hz),128.0,127.1,126.6,125.6(d, 2 J C-F =7.9 Hz),125.4,124.4(d, 4 J C-F =3.6 Hz),123.9(q, 1 J C-F =287.4 Hz),123.5(d, 3 J C-F =5.1 Hz),120.9,119.0,118.9,115.8(d, 2 J C-F =20.2 Hz),77.1(q, 2 J C-F =28.9Hz),32.8. 19 F NMR(CDCl3,565 MHz):δ-78.99(s),-124.41–-124.45(m).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 F4N3Na 420.1094;Found420.1093.

[0169] N-(2-Chlorophenyl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5al)

[0170] 1 H NMR(CDCl3,600 MHz):δ8.09(d,J=8.4 Hz,1H),8.04(d,J=7.2 Hz,1H),7.82(d,J=8.4 Hz,1H),7.43-7.41(m,1H),7.39-7.37(m,1H),7.32(dd,J1=7.2 Hz,J2=1.8Hz,1H),7.30-7.27(m,2H),7.25-7.23(m,1H),6.90-6.85(m,2H),6.45(dd,J1=8.4 Hz,J2=1.8 Hz,1H),5.64(s,1H),3.91(d,J=17.4 Hz,1H),3.63(d,J=16.8 Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,100 MHz):δ148.7,138.3,132.1,130.0,129.2,129.1,129.0,128.6,128.2,127.9,127.7,126.1,125.0,124.5(q, 1 J C-F =288.2 Hz),124.0,123.96,123.91,121.7,118.8,118.4,77.3(q, 2 J C-F =29.6 Hz),33.5. 19 F NMR(CDCl3,376 MHz):δ-78.96(s).HRMS(ESI)m / z:[M+Na] + Calcd for C 22 H 15 ClF3N3Na436.0799;Found 436.0800.

[0171] N-(Naphthalen-2-yl)-6-(trifluoromethyl)-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5am)

[0172] 1H NMR(CDCl3,400MHz):δ8.07(d,J=8.4Hz,1H),8.00(d,J=7.6Hz,1H),7.87(d,J=8.8Hz,1H),7.70(d,J=6.8Hz,1H),7.65(d,J=8.8Hz,1H),7.58(d,J=7.2Hz,1H),7.42-7.32(m,5H),7.26-7.21(m,3H),7.16(dd,J1=8.4Hz,J2=1.2Hz,1H),5.84(s,1H),3.82(d,J=16.8Hz,1H),3.59(d,J=16.8Hz,1H). 13 C{ 1 H}NMR(DMSO-d6,150MHz):δ148.6,140.5,133.9,132.0,129.7,129.4,128.9,128.6,128.5,127.7,127.5,126.9,126.6,126.2,124.6(q, 1 J C-F =288.8Hz),124.0,123.95,123.88,122.1,121.7,118.8,118.5,113.8,76.8(q, 2 J C-F =28.5Hz),33.7. 19 F NMR(CDCl3,376MHz):δ-79.16(s).HRMS(ESI)m / z:[M+Na] + Calcdfor C 26 H 18 F3N3Na452.1345;Found 452.1346.

[0173] 6-(Perfluoroethyl)-N-phenyl-5,6-dihydroindazolo[3,2-a]isoquinolin-6-amine(5an) 1 H NMR(CDCl3,400MHz):δ8.06(d,J=8.4Hz,1H),7.98(d,J=7.6Hz,1H),7.87(d,J=8.8Hz,1H),7.42-7.36(m,2H),7.26-7.22(m,3H),7.20-7.16(m,2H),7.11-7.07(m,3H),5.76(s,1H),3.64(dd,J1=16.8Hz,J2=5.2Hz,1H),3.48(d,J=17.2Hz,1H). 13C{ 1 H}NMR(DMSO-d6,150MHz): δ148.5,141.5,132.2,129.7,129.1,128.9,128 .8,128.5,127.5,126.4,123.90,123.85,123.8,123.5,121.7,119.1(qt, 1 J C-F =286.7Hz, 2 J C-F =35.0Hz),118.9,118.7,114.2(tq, 1 J C-F =266.9Hz, 2 J C-F =35.0Hz),77.7-77.4(m),33.5. 19 F NMR (CDCl3, 376MHz): δ-78.04 (s), -117.3 (d, J = 276.7Hz), -122.1 (d, J = 276.7Hz). HRMS (ESI) m / z: [M+Na] + Calcd for C 23 H 16 F5N3Na 452.1157;Found 452.1151.

[0174] Example 7

[0175]

[0176] 5aa (37.9 mg, 0.1 mmol), trifluoroethanol (1 mL) and silver acetate (83.5 mg, 0.5 mmol) were added to a 15 mL pressure tube in sequence, the reaction tube was sealed, and placed in a 140 ° C oil bath for 24 hours. After the reaction, the reaction system was cooled to room temperature, water was added to quench the reaction, and dichloromethane was extracted three times. The organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and separated by a silica gel column (petroleum ether / ethyl acetate = 20:1) to obtain a yellow solid product 3A (23 mg, 80%). The characterization data of this compound are: 1H NMR (CDCl3, 600MHz): δ8.66(d,J=7.8Hz,1H),8.39(d,J=8.4Hz,1H),8.01(d,J=8.4Hz,1H),7.91(d,J=7.8H z,1H),7.84(s,1H),7.82(t,J=7.8Hz,1H),7.62(t,J=7.2Hz,1H),7.53(t,J=7.2Hz,1H),7.35-7.32(m,1H). 13 C{ 1 H}NMR(CDCl3,150MHz): δ149.6,131.9,130.8,129.1,128.0,127.8,127.3,126.1,126.0(q, 2 J C-F =37.2Hz),122.9,122.5,120.84,120.77(q, 1 J C-F =271.2Hz),118.0,117.1(q, 3 J C-F =4.4Hz),116.2. 19 F NMR(CDCl3,565MHz):δ-67.20(s).HRMS(ESI)m / z:[M+H] + Calcdfor C 16 H 10 F3N2287.0791; Found287.0794.

[0177] Example 8

[0178] According to the method and steps of Example 7 a,b By changing compound 5, various indazole [3,2-a] isoquinoline compounds 3 with fluoromethyl groups were synthesized. The specific results are as follows:

[0179]

[0180] a Reaction conditions: 5 (0.1 mmol), silver acetate (0.5 mmol), trifluoroethanol (1 mL), 140 °C, 24 h; b Isolated yield. Representative product characterization data are as follows:

[0181] 3-Ethyl-6-(trifluoromethyl)indazolo[3,2-a]isoquinoline(3B)

[0182] 1H NMR(DMSO-d6,400MHz):δ8.81(d,J=8.4Hz,1H),8.68(d,J=8.8Hz,1H),8.38(s,1H),8.09(s,1H),7.98(d,J=8.8Hz,1H),7.84(dd,J1=8.4Hz,J2=1.2Hz,1H),7.65-7.61(m,1H),7.43-7.39(m,1H),2.86(q,J=7.6Hz,2H),1.32(t,J=7.6Hz,3H). 13 C{ 1 H}NMR(CDCl3,100MHz):δ149.6,144.4,132.0,131.4,127.9,127.4,126.4,125.8(q, 2 J C-F =36.9Hz),125.3,122.8,122.1,120.9,120.8(q, 1 J C-F =270.9Hz),117.8,117.0(q, 3 J C-F =5.1Hz),115.9,28.8,15.3. 19 F NMR(CDCl3,376MHz):δ-67.14(s).HRMS(ESI)m / z:[M+H] + Calcd for C 18 H 14 F3N2315.1104;Found 315.1108.

[0183] 6-(Trifluoromethyl)indazolo[3,2-a]isoquinoline-3-carbonitrile(3C)

[0184] 1 H NMR(CF3CO2D,400MHz):δ9.38(d,J=8.8Hz,1H),8.89-8.87(m,2H),8.66(s,1H),8.55(d,J=8.8Hz,1H),8.21(t,J=8.4Hz,1H),8.13(d,J=8.8Hz,1H),7.98(t,J=8.0Hz,1H). 13 C{ 1 H}NMR(CF3CO2D,100MHz):δ150.0(q, 2 J C-F= 47.7 Hz), 140.9, 136.0, 135.8, 134.9, 134.4, 129.3, 127.6, 127.3, 126.7, 121.9, 120.9 (q, 3 J C-F = 5.0 Hz), 116.1, 114.5, 113.1 (q, 1 J C-F = 282.4 Hz), 111.8. 19 F NMR (CDCl3, 376 MHz): δ -67.47 (s). HRMS (ESI) m / z: [M+H] + Calcd for C 17 H9F3N3 312.0743; Found 312.0745.

[0185] 2,3-Dimethoxy-6-(trifluoromethyl)indazolo[3,2-a]isoquinoline (3D)

[0186] 1 H NMR (DMSO-d6, 400 MHz): δ 8.64 (d, J = 8.4 Hz, 1H), 8.34 (s, 1H), 8.04 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.83 (s, 1H), 7.63 (t, J = 6.8 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H), 4.16 (s, 3H), 3.96 (s, 3H). 13 C{ 1 H}NMR (DMSO-d6, 150 MHz): δ 153.0, 150.3, 149.1, 131.2, 128.4, 122.4 (q, 2 J C-F = 35.1 Hz), 122.02, 121.95, 121.9, 121.5 (q, 1 J C-F = 269.1 Hz), 121.3, 117.8, 116.9, 115.1, 110.1, 103.2, 56.6, 56.2. 19 F NMR (CDCl3, 565 MHz): δ -67.04 (s). HRMS (ESI) m / z: [M+H] + Calcd for C 18 H 14 F3N2O2 347.1002; Found 347.1007.

[0187] Example 9

[0188] The anticancer activity of the compounds provided by the present invention was evaluated by studying the cell antiproliferative activity using CCK-8 assay.

[0189] The specific method is as follows: First, Hela, A549 or HCT-116 cells were inoculated into 96-well plates with 100 μL of culture medium per well at a density of 4000 cells per well, and incubated overnight at 37°C and 5% CO2. On the second day, 100 μL of the test compound prepared in culture medium at different concentrations was added to each well according to the plate map. Next, the cells were incubated for 48 hours at 37°C and 5% CO2. After the 96-well plate was equilibrated to room temperature, 10 μL of CCK-8 was added to each well and shaken on an orbital shaker for 2 minutes to induce cell lysis. Incubate for 1.5 hours at 37°C and 5% CO2, measure the absorbance at 450 nm with a multifunction microplate reader (PerkinElmer), and calculate the IC using GraphPadPrism 6.0 software. 50 All experiments were performed with two parallel samples and repeated twice. 5-Fluorouracil (5-FU) was used as a positive control for the drug.

[0190] The anticancer activity results of some compounds are as follows:

[0191]

[0192] The activity results show that the indazole [3,2-a] isoquinoline compounds 3 and 5 provided by the present invention can inhibit the proliferation activity of three types of cancer cells, Hela, A549 and HCT-116, among which compounds 3ao and 5ae have significant anti-proliferation activity against Hela cancer cells; compounds 3ea and 5ae have significant anti-proliferation activity against A549 cancer cells; 3ac, 5ac, 5ad, 5ae, 5ah, 5ai and 5am have the effect of significantly inhibiting the proliferation of HCT-116 cancer cells, indicating that this type of compound has medicinal value for preventing, treating and inhibiting the progression of cancer, especially cervical cancer, lung cancer and colon cancer.

[0193] The above embodiments describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited by the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the scope of the principles of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of protection of the present invention.

Claims

1. Indazole [3,2-a] isoquinoline compounds, the general chemical structure of which is: in: R 1 For hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen, trifluoromethyl or cyano, which is mono- or poly-substituted or forms a naphthalene ring with the benzene ring; R 2 is phenyl, substituted phenyl, naphthyl, cyclohexyl, trifluoromethyl or pentafluoroethyl, and the substituent on the phenyl ring of the substituted phenyl is a mono- or poly-substituted phenyl, C 1-4 Alkyl, C 1-4 Alkoxy, trifluoromethyl, halogen or methylenedioxy; R 3 is phenyl, substituted phenyl or naphthyl, the substituent on the phenyl ring of the substituted phenyl is C 1-4 Alkyl, C 1-4 Alkoxy, halogen, trifluoromethyl or nitro; R 4 is fluorine or trifluoromethyl.

2. Use of indazole [3,2-a] isoquinoline compounds in the preparation of anticancer active drugs, characterized in that: Indazole[3,2-a]isoquinoline compounds are Where: R 1 For hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy, phenyl, halogen, trifluoromethyl or cyano, which is mono- or poly-substituted or forms a naphthalene ring with the benzene ring; R 2 is phenyl, substituted phenyl, naphthyl, cyclohexyl, trifluoromethyl or pentafluoroethyl, and the substituent on the phenyl ring of the substituted phenyl is a mono- or poly-substituted phenyl, C 1-4 Alkyl, C 1-4 Alkoxy, trifluoromethyl, halogen or methylenedioxy; R 3 is phenyl, substituted phenyl or naphthyl, the substituent on the phenyl ring of the substituted phenyl is C 1-4 Alkyl, C 1-4 Alkoxy, halogen, trifluoromethyl or nitro; R 4 is fluorine or trifluoromethyl.

3. The use of the indazole [3,2-a] isoquinoline compound according to claim 2 in the preparation of an anticancer active drug, characterized in that: Anticancer activity is against cervical cancer, lung cancer and colon cancer.

4. The use of the indazole [3,2-a] isoquinoline compound in the preparation of an anticancer active drug according to claim 3, characterized in that: The anti-cervical cancer, lung cancer and colon cancer correspond to the anti-Hela, A549 and HCT-116 cancer cells, respectively.

5. A pharmaceutical composition for treating cervical cancer, lung cancer and colon cancer, wherein the active ingredient of the composition comprises the indazole [3,2-a] isoquinoline compound according to claim 2.

6. The method for synthesizing the indazole [3,2-a] isoquinoline compound 5 as claimed in claim 2, characterized in that: The method comprises the following steps: mixing a 3-aryl-1H-indazole compound 1, a fluoromethylimide sulfoxide ylide 4, a catalyst, an additive and an organic solvent, and heating the mixture to react to obtain a fluoromethyl-substituted indazole [3,2-a] isoquinoline compound 5, and the reaction equation is: Where: R 1 -R 4 All are consistent with claim 2.

7. The method for synthesizing the indazole [3,2-a] isoquinoline compound 5 according to claim 6, characterized in that: The additive is silver bis(trifluoromethanesulfonyl)imide, silver hexafluoroantimonate, cesium acetate or silver acetate; the organic solvent is selected from methanol, trifluoroethanol or 1,2-dichloroethane; the catalyst is selected from [RhCp*Cl2]2, [Ru(p-cymene)Cl2]2 or [IrCp*Cl2]2; the molar ratio of the 3-aryl-1H-indazole compound 1, fluoromethylimine sulfoxide ylide 4, catalyst and additive is 1:1-2:0.015-0.03:0.12-0.32; the reaction temperature is 100-140°C.

8. The method for synthesizing the indazole [3,2-a] isoquinoline compound 3 as claimed in claim 2, characterized in that: The method comprises the following steps: Method A: mixing a 3-aryl-1H-indazole compound 1, a substituted formyl sulfoxide ylide 2, a catalyst, an additive and an organic solvent, and heating the mixture to obtain an indazole [3,2-a] isoquinoline compound 3, wherein the reaction equation is: Method B: Indazole [3,2-a] isoquinoline compound 5 is reacted at elevated temperature in an organic solvent in the presence of a base to obtain indazole [3,2-a] isoquinoline compound 3. The reaction equation is: Where R 1 -R 4 All are consistent with claim 2.

9. The method for synthesizing the indazole [3,2-a] isoquinoline compound 3 according to claim 8, characterized in that: In method A, the additive is zinc trifluoromethanesulfonate or lithium trifluoromethanesulfonate; the organic solvent is a mixed solvent, preferably a mixed solvent consisting of acetic acid and trifluoroethanol, chlorobenzene or 1,2-dichloroethane; the catalyst is selected from [RhCp*Cl2]2, [RhCp*(CH3CN)3](SbF6)2 or [IrCp*Cl2]2; the molar ratio of the 3-aryl-1H-indazole compound 1, the substituted formyl sulfoxide ylide 2, the catalyst and the additive is 1:1-1.5:0.01-0.025:0.5-2; and the reaction temperature is 80-120°C.

10. The method for synthesizing the indazole [3,2-a] isoquinoline compound 3 according to claim 8, characterized in that: In method B, the base is silver acetate; the organic solvent is trifluoroethanol; and the reaction temperature is 120-150°C.